Search
Antithrombin III human
go.drugbank.com/drugs/DB11598ApprovedInvestigationalA plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Crizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigationalCrizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic … [A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTrimethaphan
go.drugbank.com/drugs/DB01116ApprovedInvestigationalA nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.
Albutrepenonacog alfa
go.drugbank.com/drugs/DB13884ApprovedAlbutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX (rFIX) with a recombinant human albumin (rAlbumin). … [A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.
Ansuvimab
go.drugbank.com/drugs/DB16385Approved[A225943, A225948, A226035] A randomized, controlled trial of four investigational therapies for Ebola virus disease (EVD) in the Democratic Republic of Congo during a previous outbreak that began in 2018 … [A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.
Avutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigational[L53203,L53198] The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, differentiation and survival. … [A273948] Avutometinib was approved by the US FDA in May 2025 in a co-package alongside [defactinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian cancer
Synonyms: N-(3-fluoro-4-((4-methyl-2-oxo-7-((pyrimidin-2-yl)oxy)-2H-1-benzopyran-3-yl)methyl)pyridin-2-yl)-N'-methylsulfuric diamide, Sulfamide, N-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-1-benzopyran-3-yl)methyl)-2-pyridinyl)-N'-methyl-Carbocromen
go.drugbank.com/drugs/DB13279ApprovedWithdrawnCarbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].
Categories: Vasodilators Used in Cardiac DiseasesVibrio cholerae CVD 103-HgR strain live antigen
go.drugbank.com/drugs/DB14443ApprovedInvestigational_Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. … prevention to become available in the U.S.
Categories: Complex MixturesBenziodarone
go.drugbank.com/drugs/DB13277ApprovedWithdrawnBenziodarone is a uricostatic and a uricosuric agent which is sold also under the name Amplivex-Labaz. It is used in the treatment of gout [A175630]. … It was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636].
Categories: Vasodilators Used in Cardiac DiseasesNADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial
go.drugbank.com/bio_entities/BE0000027TargetHumansMay be the terminally assembled subunit of Complex I … Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis.
Synonyms: Complex I-9kD